Necessity of a uniform start for scanning after FDG injection in brain PET study

Annals of Nuclear Medicine

Volumn 20, Issue 4, 2006, Pages 329-331

  Ishii, Kazunari ^a   Higashi, Yasuto ^b   Tabata, Masako ^b   Miyaishi, Masahiro ^b   Mizutani, Takashi ^b   Sasaki, Masahiro ^b  

^a Hyogo Brain and Heart Center   (Japan)

^b Himeji Central Hospital   (Japan)

Author keywords

F 18 fluorodeoxyglucose (FDG); Normal human brain; Positron emission tomography (PET); Scanning time

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBELLUM VERMIS; CINGULATE GYRUS; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; IMAGING SYSTEM; MALE; NEUROIMAGING; NORMAL HUMAN; PARIETAL LOBE; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; ARTIFACTS; BRAIN; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; INJECTIONS, INTRAVENTRICULAR; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33745815276     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF02984652     Document Type: Article

References (9)

1. Ishii K, Sakamoto S, Hosaka K, Mori T, Sasaki M. Variation in FDG uptake in different regions in normal human brain as a function of the time (30 and 60 minutes) after injection of FDG. Ann Nucl Med 2002; 16: 299-301.
2. Sakamoto S, Ishii K, Hosaka K, Mori T, Sasaki M, Mori E. Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-d-glucose. AJNR Am J Neuroradiol 2005; 26: 843-847.
3. Daube-Witherspoon ME, Matej S, Karp JS, Lewitt RM. Application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging. IEEE Trans Nucl Sci 2001; 48: 24-30.
4. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using threedimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-1248.
5. Reivich M, Alavi A, Wolf A, Greenberg JH, Fowler J, Christman D, et al. Glucose metabolic rate kinetic model parameter determination in humans: The lumped constants and rate constants for [18F]fluorode-oxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab 1985; 5: 179-192.
6. Sasaki H, Kanno I, Murakami M, Shishido F, Uemura K. Tomographic mapping of kinetic rate constants in the fluorodeoxyglucose model using dynamic positron emission tomography. J Cereb Blood Flow Metab 1986; 6: 447-454.
7. Minoshima S, Giordani B, Barent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42: 85-94.
8. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-1113.
9. 18F-FDG PET: a validation study. J Nucl Med 2005; 46: 1633-1641.